Unaudited standalone and consolidated financial result of the company for the quarter/half year ended 30 09.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited reported unaudited results for Q2 FY26 (quarter ended 30 Sept 2025) and the half year. On a standalone basis, revenue from operations for the half year was Rs. 99.96 Lacs, down about 21% from Rs. 126.54 Lacs in H1 FY25, with the company slipping into a loss of Rs. 11.09 Lacs versus a profit of Rs. 11.38 Lacs last year. On a consolidated basis, half-year revenue fell sharply to Rs. 1,449.06 Lacs from Rs. 2,547.71 Lacs (around 43% decline), driven by lower Pharma division revenue, while loss before tax widened to Rs. 531.32 Lacs (vs Rs. 24.42 Lacs loss in H1 FY25). The wholly-owned subsidiary Medgel Private Limited contributed a loss after tax of Rs. 210.80 Lacs. Standalone EPS was Rs. (0.09) versus Rs. 0.09, and consolidated EPS was Rs. (4.26) versus Rs. 0.20. The auditor (Rawka & Associates) issued an unqualified limited review report on both sets of results.
Shareholders should note a clear deterioration in profitability — both standalone and consolidated businesses swung to losses, revenue shrank sharply at the group level, and consolidated operating cash flow turned negative (Rs. 158.95 Lacs outflow). Short-term sentiment for the stock is likely negative, given the deeper losses and the subsidiary drag, though the balance sheet remains debt-free with zero borrowings.